IX-01 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Premature Ejaculation
Conditions
Premature Ejaculation
Trial Timeline
Sep 1, 2014 → Oct 1, 2015
NCT ID
NCT02232425About IX-01 + Placebo
IX-01 + Placebo is a phase 2 stage product being developed by ICON plc. for Premature Ejaculation. The current trial status is completed. This product is registered under clinical trial identifier NCT02232425. Target conditions include Premature Ejaculation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02232425 | Phase 2 | Completed |
Competing Products
8 competing products in Premature Ejaculation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| dapoxetine | Yuhan | Phase 1/2 | 41 |
| PSD502, contains a mixture of lidocaine and prilocaine + Placebo | Shionogi | Phase 2/3 | 65 |
| Placebo + Cisapride | Johnson & Johnson | Approved | 85 |
| SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ranolazine | Gilead Sciences | Phase 2 | 51 |
| Flecainide (monotherapy) | Brain Biotech | Pre-clinical | 15 |
| Tramadol Hydrochloride & Placebo | Bausch Health | Phase 3 | 72 |
| Tramadol Hydrochloride + Placebo | Bausch Health | Phase 3 | 72 |